Ly6g Activators
Ly6g Activators, specifically tailored chemical compounds, play a crucial role in modulating the functional activity of Ly6g through intricate signaling pathways. Compounds such as Rolipram, Ibudilast, Apigenin, Vinpocetine, Zardaverine, Cilostazol, Anagrelide, and Theophylline, primarily function as phosphodiesterase inhibitors (PDE3, PDE4, and non-selective PDE inhibitors). These inhibitors elevate intracellular cyclic AMP (cAMP) levels, thereby activating protein kinase A (PKA). PKA, in turn, orchestrates a cascade of phosphorylation events that regulate neutrophil functions, an essential aspect of Ly6g's role. For instance, Rolipram and Ibudilast enhance neutrophil degranulation and chemotaxis, critical functions associated with Ly6g, by sustaining elevated cAMP levels and consequent PKA activity. Similarly, compounds like Forskolin and Isoproterenol, by stimulating adenylyl cyclase, also elevate cAMP levels, further amplifying PKA-mediated signaling. This amplification is crucial for Ly6g's functional activation as it influences neutrophil migration and response to inflammatory stimuli, highlighting a strategic modulation of immune cell dynamics.
Moreover, Prostaglandin E2 (PGE2) and Milrinone, through distinct mechanisms, contribute significantly to this regulatory network. PGE2, by binding to its receptors on neutrophils, initiates a signaling cascade that culminates in increased cAMP production, mirroring the actions of PDE inhibitors. This surge in cAMP levels, akin to the effects of Milrinone's selective PDE3 inhibition, fuels PKA activation. PKA, a pivotal player in this scenario, modulates neutrophil functions, which is critical for Ly6g activation. These functions include modulation of inflammatory responses, a key aspect of Ly6g's role in immune regulation. Collectively, these Ly6g Activators, through their targeted effects on cAMP and PKA signaling, intricately enhance the functional activity of Ly6g. Their concerted action underscores a sophisticated regulation of neutrophil functions, pivotal in immune responses, thereby elucidating the essential role of these activators in the functional enhancement of Ly6g.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase-4 (PDE4) inhibitor. By inhibiting PDE4, Rolipram increases intracellular cyclic AMP (cAMP) levels. Elevated cAMP enhances the activation of protein kinase A (PKA), which can then phosphorylate downstream targets involved in immune cell regulation. This phosphorylation cascade can indirectly lead to the functional activation of Ly6g in neutrophils, as cAMP and PKA are involved in the signaling pathways that regulate neutrophil functions such as degranulation and chemotaxis. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its receptors on neutrophils, leading to the activation of adenylate cyclase and subsequent increase in cAMP levels. This rise in cAMP enhances PKA activity, which is known to regulate neutrophil functions including those associated with Ly6g activation, such as modulation of inflammatory responses. | ||||||
Ibudilast | 50847-11-5 | sc-203080 | 10 mg | $218.00 | 1 | |
Ibudilast is a PDE4 inhibitor, similar to Rolipram. It increases cAMP levels in neutrophils, leading to PKA activation. PKA then influences the signaling pathways that are involved in neutrophil activation and function, which can indirectly enhance the activity of Ly6g in these immune cells. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that stimulates adenylyl cyclase, leading to increased cAMP production. This surge in cAMP activates PKA, which then modulates signaling pathways in neutrophils, potentially influencing Ly6g activation through regulation of migration and response to inflammatory stimuli. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin is a flavone that can inhibit PDE4, resulting in increased cAMP levels and subsequent PKA activation. Through PKA, apigenin can modulate neutrophil functions, which may include the functional activity of Ly6g, especially in inflammatory and immune responses. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a selective PDE3 inhibitor. While its primary action is on cardiac muscle, its inhibition of PDE3 can also lead to increased cAMP levels in neutrophils. Elevated cAMP and PKA activation can influence neutrophil functions, potentially enhancing the activity of Ly6g in these cells. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor. By inhibiting PDE1, it can indirectly increase cAMP levels in neutrophils, leading to PKA activation. This activation may influence the signaling pathways involving Ly6g, particularly in regulating neutrophil response to inflammatory stimuli. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a selective inhibitor of both PDE3 and PDE4. This dual inhibition results in increased cAMP levels in neutrophils, enhancing PKA activity. PKA can modulate neutrophil functions, including those associated with Ly6g, particularly in inflammation and immune response. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a PDE3 inhibitor that increases cAMP in cells, leading to PKA activation. This can affect neutrophil functions by influencing signaling pathways that involve Ly6g, particularly in modulating inflammatory responses and chemotaxis. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is another PDE3 inhibitor that raises cAMP levels, leading to PKA activation. Enhanced PKA activity can modulate neutrophil functions, which may include the activation of Ly6g, especially in the context of inflammation and immune responses. | ||||||